The expanding role of active surveillance in urology

It is fascinating to see that, as urologists have begun to understand and accept the viability and value of active surveillance (“expectant management”) in management of prostate cancer, they are beginning to see other uses for this strategy too. … READ MORE …

Sticks and stones can break your bones, and words can really hurt you

Smart physicians have always been extremely conscious that how they present information can have a profound impact on exactly how patients will react to that information. … READ MORE …

Selection of appropriate candidates for management with active surveillance

In this month’s issue of the Journal of Urology, Dr. Peter Carroll (of UCSF) and Dr. Mark Dall’Era (formerly of UCSF and now at UCDavis) have contributed an editorial entitled “What is the optimal way to select candidates for active surveillance of prostate cancer?” … READ MORE …

Active surveillance, upgrading on repeat biopsy, and consequent management

In February this year we commented on an article that argued in favor of active surveillance as an appropriate initial management strategy for “favorable” intermediate-risk prostate cancer. … READ MORE …

Other items from the annual meeting of the AUA

A combination of travel and other commitments made it difficult for your sitemaster to complete his summaries of significant information presented at this year’s annual meeting of the American Urological Association (AUA), so here’s the final wrap-up. … READ MORE …

Active surveillance today: a summary of the Sunnybrook experience and related factors

In an important new paper in Current Opinion in Urology (available free as a full-text article), Dr. Laurie Klotz has provided an excellent summary of his perspective on the current application of active surveillance in the management of low-risk prostate cancer, based on the 20-year experience of the Sunnybrook group and other data. … READ MORE …

Active surveillance is absolutely NOT appropriate for all men with intermediate-risk prostate cancer

A paper to be presented this Thursday at the upcoming Genitourinary Cancers Symposium in  Orlando, Florida, will clearly confirm the above heading, which should come as no surprise to anyone. The issue has always been whether there is a subset of men with (“favorable”) intermediate-risk disease who are potentially appropriate candidates. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,351 other followers